TY - JOUR
TI - Elevated MICs of susceptible antipseudomonal cephalosporins in non-carbapenemase-producing, carbapenem-resistant pseudomonas aeruginosa: Implications for dose optimization
AU - Gill, C.M.
AU - Aktaş, E.
AU - Alfouzan, W.
AU - Bourassa, L.
AU - Brink, A.
AU - Burnham, C.-A.D.
AU - Canton, R.
AU - Carmeli, Y.
AU - Falcone, M.
AU - Kiffer, C.
AU - Marchese, A.
AU - Martinez, O.
AU - Pournaras, S.
AU - Seifert, H.
AU - Thabit, A.K.
AU - Villegas, M.V.
AU - Westblade, L.F.
AU - Nicolau, D.P.
AU - Wille, J.
AU - Rezende, T.T.F.
AU - Cekin, Z.
AU - Malkocoglu, G.
AU - Gijón, D.
AU - Tarakmeh, L.A.
AU - Chu, C.Y.
AU - Opperman, C.J.
AU - Tootla, H.D.
AU - Moodley, C.
AU - Coetzee, J.
AU - Vourli, S.
AU - Dimopoulos, G.
AU - Attallah, D.M.
AU - Tiseo, G.
AU - Leonildi, A.
AU - Giordano, C.
AU - Barnini, S.
AU - Menichetti, F.
AU - Di Pilato, V.
AU - Codda, G.
AU - Vena, A.
AU - Giacobbe, D.R.
AU - Satlin, M.
AU - Cardona, A.
AU - Curtis, L.
AU - Fang, F.
AU - Thomson, G.
AU - Thomson, K.
AU - the ERACE-PA Global Study Group
JO - Antimicrobial Agents and Chemotherapy
PY - 2021
VL - 65
TODO - 11
SP - null
PB - American Society for Microbiology
SN - 0066-4804, 1098-6596
TODO - 10.1128/AAC.01204-21
TODO - cefepime;  ceftazidime;  antiinfective agent;  azabicyclo derivative;  carbapenem derivative;  ceftazidime;  cephalosporin derivative, antibiotic sensitivity;  Article;  bacterium isolate;  carbapenem resistant Pseudomonas aeruginosa;  clinical laboratory standard;  controlled study;  dose calculation;  drug potency;  in vitro study;  maximum permissible dose;  MIC50;  MIC90;  Monte Carlo method;  nonhuman;  process optimization;  human;  microbial sensitivity test;  Pseudomonas aeruginosa;  Pseudomonas infection, Anti-Bacterial Agents;  Azabicyclo Compounds;  Carbapenems;  Ceftazidime;  Cephalosporins;  Humans;  Microbial Sensitivity Tests;  Pseudomonas aeruginosa;  Pseudomonas Infections
TODO - The present study evaluated the in vitro potency of ceftazidime and cefepime among carbapenem-resistant Pseudomonas aeruginosa isolates collected as part of a global surveillance program and assessed the pharmacodynamic implications using previously published population pharmacokinetics. When susceptible, MICs resulted at the high end of distribution for both ceftazidime and cefepime, thus 6 g/day was required to achieve optimal pharmacodynamic profiles. These findings should be considered in the clinic and for the application of CLSI susceptibility breakpoints. © 2021 American Society for Microbiology.
ER -